Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) traded up 3.2% on Thursday. The company traded as high as $15.1850 and last traded at $15.04. Approximately 1,136,185 shares were traded during mid-day trading, an increase of 2,020% from the average daily volume of 53,591 shares. The stock had previously closed at $14.57.
Aerovate Therapeutics Price Performance
The company has a 50 day moving average price of $15.93 and a 200-day moving average price of $18.15. The stock has a market capitalization of $436.80 million, a PE ratio of -5.04 and a beta of 0.95.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary arterial hypertension (PAH), a progressive disorder involving elevated blood pressure in the arteries of the lungs. The company was headquartered in Cambridge, Massachusetts, and its research programs were aimed at addressing the underlying vascular changes associated with pulmonary diseases.
Aerovate’s lead product candidate was AV-101, an inhaled dry-powder formulation of imatinib, a tyrosine kinase inhibitor.
Further Reading
- Five stocks we like better than Aerovate Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.jpg){kind=logo}
